The One Big Beautiful Bill Act (OBBBA) of 2025 has generated controversy across numerous areas of social policy. However, one aspect of the bill has received relatively little...
On January 17, 2025, the Centers for Medicare & Medicaid Services announced the next round of drugs to be negotiated by Medicare. This round includes 15 drugs, with...
Developments in the first half of 2024 show companies responding to a significantwave of patent expirations, which will continue through the 2nd half of this decade.Macroeconomic factors have...
In this report, we continue our evaluation through the end of 2024, with the additional context of the 2025 implementation of the Part D redesign as well as...
In August, the Biden administration marked an important moment in the history of Medicare. For the first time, the program completed negotiations with pharmaceutical manufacturers to establish what...
Partner with Verdant for rigorous, objective economic analysis.